BioCentury
ARTICLE | Clinical News

VAL-083: Ph II started

January 27, 2017 4:34 AM UTC

DelMar began an open-label, U.S. Phase II trial to evaluate 40 mg/m2 IV VAL-083 on days 1-3 of each 21-day cycle for up to 12 cycles in about 48 patients with O6-alkylguanine alkyltransferase (MGMT)-u...

BCIQ Company Profiles

Kintara Therapeutics Inc.